Cart
sales@molnova.com
GLP-1R modulator L7-028
CAS No. 2648317-95-5
GLP-1R modulator L7-028( —— )
Catalog No. M35193 CAS No. 2648317-95-5
GLP-1R modulator L7-028 is a variant that enhances affinity for GLP-1 and (cAMP) signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 132 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 322 | In Stock |
|
| 50MG | 460 | In Stock |
|
| 100MG | 684 | In Stock |
|
| 200MG | 918 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGLP-1R modulator L7-028
-
NoteResearch use only, not for human use.
-
Brief DescriptionGLP-1R modulator L7-028 is a variant that enhances affinity for GLP-1 and (cAMP) signaling.
-
DescriptionGLP-1R modulator L7-028 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 11.01 ± 2.73 μM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor | cAMP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2648317-95-5
-
Formula Weight392.49
-
Molecular FormulaC24H28N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (254.78 mM; Ultrasonic )
-
SMILESO=C(Nc1cccc(c1)C(=O)N1CCCCC1)c1cccc(OC2CCCC2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PF-06882961 Tris
PF-06882961 Tris is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist.
-
PF-06882961
PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.
-
Bay 55-9837
Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC1 agonists.
